Stage I Grade 3 Follicular Lymphoma Completed Phase 2 Trials for Pegfilgrastim (DB00019)

IndicationStatusPhase
DBCOND0029477 (Stage I Grade 3 Follicular Lymphoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01682044Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone LymphomaTreatment